CONSIDER SELL SHORT MRNA (MDRNA)
We are short from $3.51 in pre market as our analysis does not justify the share price appreciation from the approval of generic calcitonin-salmon nasal spray for the treatment of osteoporosis www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .